search

Active clinical trials for "Amyotrophic Lateral Sclerosis"

Results 41-50 of 757

Amyotrophic Lateral Sclerosis Non-invasive Ventilation Exchange

Amyotrophic Lateral Sclerosis

The median survival of patients with amyotrophic lateral sclerosis (ALS) is 3 to 5 years and mortality is mainly related to respiratory failure. Non-invasive ventilation (NIV) and multidisciplinary management improve the quality of life and survival of patients. However, patients have mobility difficulties related to the progressive worsening of functional disabilities. The research team hypothesize that the use of a multimodal digital platform, including in particular telemonitoring of NIV and teleconsultation, will slow down the evolution of the disabilities of patients with ALS and improve their quality of life.

Recruiting13 enrollment criteria

A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients...

Amyotrophic Lateral Sclerosis

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Recruiting10 enrollment criteria

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

Recruiting10 enrollment criteria

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis...

Amyotrophic Lateral Sclerosis

This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.

Recruiting18 enrollment criteria

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Amyotrophic Lateral Sclerosis

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Recruiting11 enrollment criteria

Ambulatory Versus Inpatient Initiation of Home Mechanical Ventilation

Amyotrophic Lateral Sclerosis

The purpose of this investigation is to see if outpatient initiation of noninvasive home mechanical ventilation combined with closed telemonitoring and follow-up in patients with amyotrophic lateral sclerosis is non-inferior to initiation during admission to the hospital The primary hypothesis is that outpatient intiation of noninvasive home mechanical ventilation combined with closed telemonitoring and follow-up is non-inferior to initiation during hospitalization in patients with amyotrophic lateral sclerosis.

Recruiting8 enrollment criteria

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.

Enrolling by invitation5 enrollment criteria

AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic...

Parkinson DiseaseAmyotrophic Lateral Sclerosis

The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).

Recruiting18 enrollment criteria

A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801...

Amyotrophic Lateral Sclerosis (ALS)

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients with Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)

Recruiting40 enrollment criteria

Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With...

Gene Mutation

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation. Patients will receive drug treamtent via dose escalation which ranging from minimum of 60 mg to the maximum tolerated dose (MTD), after reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months. The duration of this study is two years.

Enrolling by invitation24 enrollment criteria
1...456...76

Need Help? Contact our team!


We'll reach out to this number within 24 hrs